Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...

When scientists sliced into a block of Siberian permafrost and pulled out a woolly mammoth nicknamed Yuka, they expected to ...

A research team at The University of Osaka revealed that the loss of heterochromatin can cause a chain reaction leading to ...

Accomplished RNA therapeutics leader with track record of advancing novel genetic medicines from discovery to FDA approval to ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

A new review highlights major advances in a promising class of diagnostic tools known as aptamer-based biosensors, which ...

The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Nick Edwards, PhD, CEO of Potato, has a “burning desire” to speed up scientific discovery. In an interview with GEN, he explained how Potato’s AI “scientist,” named Tater, recently replicated a main ...

The current study explored how macronutrients in the host diet are involved in gut colonization and competition by V.

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we ...